Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
Julian Adams, PhD
Advertisement
Articles by Julian Adams, PhD
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.
Advertisement
Latest Updated Articles
The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin LymphomaPublished: July 3rd 2014 | Updated:
The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLLPublished: August 28th 2014 | Updated:
The Phase I Trial of IPI-145 in Hematologic MalignanciesPublished: June 21st 2013 | Updated:
An Overview of the Treatment of Hematologic MalignanciesPublished: August 13th 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
